General information about company

Scrip code*543213
NSE Symbol*ROSSARI
MSEI Symbol*NOTLISTED
ISIN*INE02A801020
Name of companyROSSARI BIOTECH LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved19-07-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange11-07-2025
Description of presentation currencyINR
Level of roundingMillions
Reporting TypeQuarterly
Reporting QuarterFirst quarter
Nature of report standalone or consolidatedStandalone
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment ReportingSingle segment
Description of single segmentManufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries
Start date and time of board meeting19-07-2025 17:45
End date and time of board meeting19-07-2025 18:45
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?Yes



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-04-202501-04-2025
Date of end of reporting period30-06-202530-06-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations3657.583657.58
Other income17.4217.42
Total income36753675
2Expenses
(a)Cost of materials consumed2117.432117.43
(b)Purchases of stock-in-trade500.84500.84
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade93.493.4
(d)Employee benefit expense 156.66156.66
(e)Finance costs30.9330.93
(f)Depreciation, depletion and amortisation expense71.571.5
(g)Other Expenses
1Other Expenses349.8349.8
Total other expenses349.8349.8
Total expenses3320.563320.56
3Total profit before exceptional items and tax354.44354.44
4Exceptional items 00
5Total profit before tax354.44354.44
6Tax expense
7Current tax96.4296.42
8Deferred tax-4.31-4.31
9Total tax expenses92.1192.11
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations262.33262.33
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method00
16Total profit (loss) for period262.33262.33
17Other comprehensive income net of taxes-0.7-0.7
18Total Comprehensive Income for the period261.63261.63
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital110.73110.73
Face value of equity share capital22
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations4.744.74
Diluted earnings (loss) per share from continuing operations4.734.73
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations4.744.74
Diluted earnings (loss) per share from continuing and discontinued operations4.734.73
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Text Block

Textual Information(4)Notes
1.The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 19th July, 2025.2.The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard Ind AS 34 on Interim Financial Reporting as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, as amended.3.The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.4.The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.5.During the quarter ended 30th June, 2025, the Company has allotted 2,825 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan 2019. 6.Previous year period figures have been regrouped to make them comparable with the current year period figures, which are not material.
For ROSSARI BIOTECH LIMITED
EDWARD MENEZES
Executive Chairman
DIN 00149205
Place Mumbai
Date 19th July, 2025



Other Comprehensive Income

Date of start of reporting period01-04-202501-04-2025
Date of end of reporting period30-06-202530-06-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1Remeasurements of the defined benefit plans-0.94-0.94
Total Amount of items that will not be reclassified to profit and loss-0.94-0.94
2Income tax relating to items that will not be reclassified to profit or loss -0.24-0.24
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss 0.000.00
5Total Other comprehensive income-0.70-0.70


Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No.ParticularsAmountRemarks
1.Loans / revolving facilities like cash credit from banks / financial institutions
ATotal amount outstanding as on date0
BOf the total amount outstanding, amount of default as on date0
2.Unlisted debt securities i.e. NCDs and NCRPS
ATotal amount outstanding as on date0
BOf the total amount outstanding, amount of default as on date0
3.Total financial indebtedness of the listed entity including short-term and long-term debt0